415 terminated. 415 Phase 3, 72 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 415 | Terminated 415 |
| Phase 2 | 72 | Terminated 72 |
Follow Digestive System Diseases: new trials by email Literature Review of Digestive System Diseases trials Research Report on Digestive System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma Best Supportive Care, Balstilimab, Botensilimab - Colorectal Cancer | Phase 3 | Terminated | Canadian Cancer Trials Group | 21 | 2026-03-31 | 2026-07-16 |
| Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio AVT16, Vedolizumab - Ulcerative Colitis | Phase 3 | Terminated | Alvotech Swiss AG | 301 | 2024-09-23 | 2025-12-26 |
| Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy OCA, Matching Placebo - Biliary Atresia | Phase 2 / Phase 3 | Terminated | Intercept Pharmaceuticals | 28 | 2024-09-02 | 2026-07-07 |
| Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN) Metoprolol Injection, saline 0.9% - Acute Respiratory Distress Syndrome (ARDS) | Phase 3 | Terminated | Consorcio Centro de Investigación Biomédica en Red (CIBER) | 14 | 2024-07-10 | 2026-06-02 |
| To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate FDC tablet (OCA 5 mg + BZF 400 mg SR) - Primary Biliary Cholangitis | Phase 3 | Terminated | Intercept Pharmaceuticals | 62 | 2024-07-01 | 2026-06-08 |
| NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients MAP-Target Algorithm - Acute Kidney Injury, Cirrhosis | Phase 2 / Phase 3 | Terminated | University of California, San Francisco | 14 | 2024-02-01 | 2026-09-24 |
| Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7 Regorafenib in combination with pembrolizumab, Loco-regional therapy - Carcinoma, Hepatocellular | Phase 3 | Terminated | Translational Research in Oncology | 45 | 2023-10-11 | 2026-03-09 |
| A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy Ozanimod - Crohn Disease | Phase 2 / Phase 3 | Terminated | Bristol-Myers Squibb | 5 | 2023-08-22 | 2025-04-22 |
| Effect of Fecal Microbiota Transplantation (FMT) in Pediatric Functional Gastrointestinal Disorders FMT, Conventional drugs - Functional Gastrointestinal Disorders | Phase 3 | Terminated | Biao Zou | 47 | 2023-04-03 | 2026-08-03 |
| Efficacy and Safety of Hemorrane Plus Versus Hemorrane and Versus Placebo in Patients With Uncomplicated Haemorrhoids Hemorrane plus, Hemorrane, Placebo - Haemorrhoids Without Complication | Phase 3 | Terminated | Faes Farma, S.A. | 21 | 2023-03-30 | 2024-02-28 |
| A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection Guselkumab, Placebo - Crohn's Disease | Phase 3 | Terminated | Janssen Research & Development, LLC | 4 | 2023-02-21 | 2025-04-29 |
| A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC) Ozanimod, Placebo - Ulcerative Colitis | Phase 3 | Terminated | Bristol-Myers Squibb | 131 | 2022-12-09 | 2025-03-26 |
| A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Abelacimab, Dalteparin - Venous Thromboembolism, Deep Venous Thrombosis | Phase 3 | Terminated | Anthos Therapeutics, Inc. | 417 | 2022-09-27 | 2026-04-17 |
| A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission Filgotinib, Placebo - Ulcerative Colitis | Phase 3 | Terminated | Lakefront Biotherapeutics NV | 22 | 2022-07-26 | 2024-10-04 |
| A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection LB1148, Placebo - Ileus, Gastro-Intestinal Disorder | Phase 3 | Terminated | Palisade Bio | 23 | 2022-06-28 | 2024-06-13 |
| Efficacy and Safety of Two Doses of HIL-214 in Children HIL-214, Placebo - Gastroenteritis | Phase 2 / Phase 3 | Terminated | HilleVax | 3084 | 2022-04-28 | 2025-07-10 |
| A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer Nivolumab-relatlimab FDC, Regorafenib, TAS-102 - Colorectal Neoplasms | Phase 3 | Terminated | Bristol-Myers Squibb | 769 | 2022-04-28 | 2026-08-26 |
| Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer Futuximab/modotuximab, Trifluridine/Tipiracil - Metastatic Colorectal Cancer | Phase 3 | Terminated | Institut de Recherches Internationales Servier | 7 | 2022-04-21 | 2024-08-20 |
| Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer D07001-softgel capsules + Xeloda (or TS-1), mFOLFOX - Biliary Tract Cancer | Phase 2 / Phase 3 | Terminated | InnoPharmax Inc. | 19 | 2022-03-29 | 2026-11-04 |
| Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. Bemarituzumab, Nivolumab, Chemotherapy - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Terminated | Amgen | 515 | 2022-03-14 | 2026-09-10 |
Showing 20 of 415. Sign in to see all of them.
Colorectal Neoplasms (43) · Crohn Disease (43) · Carcinoma, Hepatocellular (30) · Colitis, Ulcerative (30) · Pancreatic Neoplasms (27) · Colonic Neoplasms (26) · Rectal Neoplasms (22) · Stomach Neoplasms (21) · Hepatitis C (19) · Inflammatory Bowel Diseases (19) · Hepatitis C, Chronic (18) · Hepatitis B (15) · Cystic Fibrosis (13) · Neoplasm Metastasis (12) · Neoplasms (12)
Gastrointestinal Diseases (241) · Digestive System Neoplasms (166) · Neoplasms (165) · Intestinal Diseases (162) · Neoplasms by Site (160) · Pathological Conditions, Signs and Symptoms (120) · Liver Diseases (106) · Gastrointestinal Neoplasms (100) · Gastroenteritis (92) · Colonic Diseases (91) · Pathologic Processes (87) · Intestinal Neoplasms (65) · Neoplasms by Histologic Type (63) · Rectal Diseases (61)
Fluorouracil (29) · Capecitabine (21) · Leucovorin (21) · Oxaliplatin (19) · Cisplatin (18) · Ribavirin (17) · Gemcitabine (14) · peginterferon alfa-2a (12) · Irinotecan (11) · Bevacizumab (10) · peginterferon alfa-2b (9) · Mesalamine (8) · Imatinib Mesylate (7) · Sorafenib (7) · clevudine (6)
Merck Sharp & Dohme LLC (13) · Assistance Publique - Hôpitaux de Paris (8) · Bristol-Myers Squibb (7) · Gilead Sciences (7) · Sanofi (7) · GlaxoSmithKline (6) · Hoffmann-La Roche (6) · M.D. Anderson Cancer Center (6) · Novartis Pharmaceuticals (6) · Shire (6) · Allergan (5) · Celgene (5) · French National Agency for Research on AIDS and Viral Hepatitis (5) · Janssen Research & Development, LLC (5) · NSABP Foundation Inc (5)
United States (221) · France (118) · Germany (109) · Spain (102) · Canada (101) · Italy (93) · United Kingdom (86) · Belgium (85) · South Korea (75) · Australia (74) · Poland (74) · Hungary (60) · Israel (59) · Taiwan (53) · Austria (48)
Norman Wolmark, MD (5) · Hyo-Suk Lee, MD. PhD (3) · Charles Blanke (2)
PMID 36208720, PMID 38096402, PMID 21836029, PMID 28543263, PMID 28707787, PMID 28707796, PMID 29508247, PMID 30639779, PMID 30779990, PMID 31271665, PMID 32147362, PMID 32445184, PMID 33307033, PMID 33331662, PMID 36308441, PMID 36750244, PMID 37983082, PMID 40013523, PMID 15050885, PMID 16887481, PMID 17593061, PMID 17635375, PMID 17647293, PMID 17850410, PMID 17985376, PMID 18266048, PMID 18266997, PMID 18378608, PMID 18378947, PMID 18477354, PMID 19053983, PMID 19585548, PMID 19643599, PMID 20203173, PMID 20489620, PMID 20724077, PMID 20925534, PMID 20937118, PMID 20947884, PMID 21060024, PMID 21104822, PMID 21140148, PMID 21306237, PMID 21688345, PMID 21831266, PMID 21890814, PMID 21918956, PMID 22504093, PMID 22913681, PMID 23060037
2017 (12), 2019 (10), 2015 (7), 2016 (7), 2009 (5), 2018 (5), 2014 (4), U10CA032102 (4), 2008 (3), 2023 (3), U10CA180888 (2), 2005 (1), K23CA115908 (1), M01RR000040 (1), N01CM17003 (1)